L3VLUP
ProSign in

SYK · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SYKVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SYK
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSYKVRTX
Q3 202019 holders, $10.7bn31 holders, $21.9bn
Q4 202015 holders, $13.5bn30 holders, $18.4bn
Q1 202121 holders, $14.0bn31 holders, $15.4bn
Q2 202120 holders, $15.4bn30 holders, $12.7bn
Q3 202120 holders, $15.9bn35 holders, $10.1bn
Q4 202122 holders, $15.9bn28 holders, $12.4bn
Q1 202221 holders, $16.1bn23 holders, $16.1bn
Q2 202221 holders, $11.4bn25 holders, $18.1bn
Q3 202214 holders, $12.1bn22 holders, $18.4bn
Q4 202215 holders, $14.5bn28 holders, $18.4bn
Q1 202317 holders, $17.5bn26 holders, $21.4bn
Q2 202323 holders, $16.9bn27 holders, $24.7bn
Q3 202321 holders, $14.0bn33 holders, $24.3bn
Q4 202322 holders, $14.9bn32 holders, $28.6bn
Q1 202424 holders, $16.9bn31 holders, $29.8bn
Q2 202423 holders, $15.3bn29 holders, $33.4bn
Q3 202420 holders, $15.5bn27 holders, $33.5bn
Q4 202421 holders, $14.8bn26 holders, $28.5bn
Q1 202518 holders, $14.8bn21 holders, $35.4bn
Q2 202521 holders, $16.8bn21 holders, $32.3bn
Q3 202523 holders, $15.1bn22 holders, $25.9bn
Q4 202525 holders, $14.0bn26 holders, $31.8bn
Q1 202629 holders, $14.0bn25 holders, $31.8bn
Q2 202618 holders, $11.4bn26 holders, $34.6bn
SYK

Stryker Corporation

Holders
24
Reported value
$16.9bn
Buyers
11
Sellers
15

Breadth -4 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SYK (4)

Arrowstreet Capital LP, GAMCO Investors Inc, Quantbot Technologies LP, Woodline Partners LP

Only VRTX (11)

ARK Investment Management LLC, Capital World Investors, Caxton Associates LLP, ExodusPoint Capital Management LP, Man Group PLC, Millennium Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Advisers LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →